Thyrocare Technologies Limited (THYROCARE) Share Price
NSE · Healthcare · Diagnostics & Research · ISIN INE594H01019
Key metrics
- Market Cap
- ₹9,210 Cr
- P/E Ratio
- 52.51
- EPS
- 11.02
- Book Value
- 36.82
- P/B Ratio
- 15.74
- ROE
- 27.82%
- ROCE
- 32.14%
- Debt / Equity
- 0.09
- Net Margin
- 19.84%
- Revenue Growth
- 20.74%
- Profit Growth
- 78.17%
- Dividend Yield
- 2.83%
- 52W High
- ₹662.00
- 52W Low
- ₹342.55
- Market Cap Band
- mid cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
- Headquarters
- Navi Mumbai, India
- Employees
- 1,906
- Promoter Holding
- 51.18%
The full Thyrocare Technologies Limited analysis
Create a free account to open the complete THYROCARE deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.